Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 3Testicular Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Renal Insufficiency 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Failure 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × veliparib × Genitourinary × Clear all
NCT01576172 2020-11-12

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
159 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT01085422 2017-11-21

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

AbbVie

Phase 1 Completed
35 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡